858 Therapeutics Secures $50M Series B Financing to Advance Oncology Therapeutics
Slice of Healthcare Team
Oct 03, 2024
Key Highlights
- 858 Therapeutics raises $50M in Series B financing led by Avidity Partners.
- Proceeds to advance ETX-19477, a selective PARG inhibitor for cancer treatment.
- Phase 1 clinical trials of ETX-19477 are underway in patients with advanced solid tumors.
- Strong support from life science investors including Avidity Partners, Insight Partners, and others.
Source: Business Wire
Notable Quotes
“ The Series B financing is a testament to the 858 team and the progress we’ve made across our portfolio, including the advancement of our PARG inhibitor ETX-19477 into the clinic. ”
Jeffrey Stafford, Ph.D., CEO at 858 Therapeutics
“ We are excited to partner with the company to help address unmet needs across a variety of disease types in an effort to bring transformative medicines to patients. ”
Monal Mehta, Ph.D., Managing Director at Avidity Partners
